{"id":"W2129508275","doi":"10.14694/edbook_am.2015.35.e41","title":"Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease","year":2015,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Clinical trial; Disease; Chemotherapy; Adjuvant; Metastatic breast cancer; Pertuzumab; Adjuvant therapy; Cancer; Targeted therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.002218727,0.0003829131,0.004168154,0.00006306208,0.00008095549,0.000009742988,0.0002834856,0.0004026704,0.000315116],"category_scores_gemma":[0.001479421,0.0002929014,0.001779703,0.0002332799,0.003337992,0.00005030027,0.0001134316,0.0009459655,0.00003312015],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006473897,"about_ca_system_score_gemma":0.03375455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008615544,"about_ca_topic_score_gemma":0.000002112781,"domain_scores_codex":[0.9959674,0.0005707418,0.001698257,0.0007855772,0.0005605419,0.0004174464],"domain_scores_gemma":[0.9873059,0.008845156,0.001317695,0.0004968201,0.0009708525,0.001063535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003317342,0.00100772,0.0004672713,0.001637553,0.0006322459,0.000002566958,0.0001371654,6.617326e-8,9.676116e-8,0.0001711716,0.1889804,0.806632],"study_design_scores_gemma":[0.001488246,0.003895989,0.003350817,0.002091225,0.0009157907,0.00002174627,0.000191741,0.00001163282,1.250891e-7,0.000347659,0.9874375,0.0002474778],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004749947,0.962302,0.00002898282,0.03262757,0.0003967773,0.002781108,0.0003034133,0.00001816801,0.001494423],"genre_scores_gemma":[0.00001354282,0.9686348,0.007529531,0.01045779,0.001941763,0.0009578268,0.0005664943,0.00007620919,0.009822065],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8063845,"threshold_uncertainty_score":0.9999523,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3077707158593259,"score_gpt":0.6224921145437846,"score_spread":0.3147213986844588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}